Dr. Rachel Pessah Pollack Breaks Down Retatrutide's Expanded Access

Our Take

Key points from the segment

• Lilly reports patients in clinical trials lost 73 to 85 pounds over two years.
• Retatrutide adds a third hormonal pathway (glucagon) on top of the GLP-1 and GIP targets used by Wegovy and Zepbound.
• Patients with a BMI of 35 or higher could potentially lose up to 30% of body weight over two years in clinical trials — roughly one in five obese Americans falls into this BMI range.
• Side effects mirror other GLP-1 drugs: nausea, vomiting, constipation, and diarrhea.
• Dr. Pessah Pollack expects the biggest benefit for patients with weight-related complications — cardiac disease, sleep apnea, and knee arthritis limiting mobility.
• She calls Lilly's new expanded access pathway a "game-changer" for select patients who can't wait for FDA approval.

Where this fits

This segment is the mainstream-news counterpart to the PolitiFact piece elsewhere in this hub, which covered the original single-patient compassionate use case. That case is now the exception that led here: Eli Lilly confirmed on August 3, 2026 that it has formalized an expanded access program with defined eligibility criteria, including being 18 or older, having refractory obesity despite maximal-dose therapy, and having at least two serious or life-threatening obesity-related complications. The program remains narrow by design — most patients won't qualify — but it's a meaningful shift from the company's earlier silence on the topic.

Retatrutide remains investigational. Eli Lilly has said it plans to file a Biologics License Application (BLA) with the FDA in Q1 2027; approval is not guaranteed and the drug is not legally available outside a clinical trial or this narrow expanded access pathway.